Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The First Discrete Choice Experiment on Usage of Bypassing Agents in Hemophilic Patients in Iran



Habibpanah B1 ; Tara Z1 ; Malek F1 ; Ardeshiri R2 ; Salimi T3 ; Saafi A4 ; Fasih B5 ; Managhchi MR6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Pediatric Congenital Hematologic Disorders Research Center, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Shahid Dastgheib Hemophilia Center, Shiraz University of Medical Sciences, Shiraz, Iran
  3. 3. Comprehensive Hemophilia Care Center, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Hematology and oncology center, Omid Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Aliasghar Hospital, Zahedan University of medical sciences, Zahedan, Iran
  6. 6. Thrombosis Hemostasis Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Blood and Cancer Published:2016

Abstract

Background: Bleeding events in hemophilic patients with inhibitors are managed by bypassing agents. Currently available agents in Iran are recombinant activated factor VII (rfVIIa; Aryogen, Aryoseven) and Feiba (factor eight inhibitor bypassing agent). No standardized and accurate assay is currently available for monitoring the effectiveness of bypassing agents. We suggested that history of the patients’ response and also their preference could be a reliable method for assessing the efficacy of bypassing agents; therefore, we designed a multi-centric discrete choice experiment study to assess the factors that affect the efficacy of bypassing agents. Methods: Hemophilic patients older than 2 years with inhibitors who required bypassing agents for the treatment of bleeding episodes were eligible to participate in the study. Patients’ preference toward treatment with either Feiba or Aryoseven was measured with a DCE (discrete choice experiment) design on a phone interview. Results: 80 patients were enrolled from 5 centers in Iran. At enrollment, the mean age was18.6 years (range, 2-50 years). 47 patients (58%) preferred to receive FEIBA, 21 patients (21.2%) favored Aryoseven and 12 (14.8%) patients claimed no difference between the two products. Conclusion: Our results indicated that according to the DCE method, patients preferred Feiba to Aryoseven while the main reason was their higher efficacy. In addition, adverse reactions in both groups were almost equal. As a result, it seems that presence of both products in the market for hemophilic patients with inhibitors is absolutely essential. © 2016 Iranian Pediatric Hematology and Oncology Society. All rights reserved.
Related Docs
1. Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor Vii (Aryoseven™) and Activated Prothrombin Complex Concentrates (Feiba™) to Treat Hemophilia a Patients With Inhibitors in Iran, Iranian Journal of Pharmaceutical Research (2016)
2. A Comparison of Efficacy Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Hereditary Fviii Deficiency With Inhibitor, Clinical and Applied Thrombosis/Hemostasis (2016)
3. A Randomized, Two-Armed, Double-Blind, Single-Dose, Cross-Over, Bioequivalence Clinical Trial to Compare Pharmacokinetic Parameters and Safety of Recombinant Human Factor Viii With Fc Fusion Produced by Aryogen Pharmed Company Versus Elocta® (Reference Product) in Previously Treated Patients With Severe Haemophilia A, Annals of Hematology (2025)
4. Comparative Evaluation of the Safety and Efficacy of Recombinant Fviii in Severe Hemophilia a Patients, Journal of Pharmacopuncture (2018)
5. A Comparison Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Congenital Factor Vii Deficiency, Clinical and Applied Thrombosis/Hemostasis (2015)
Experts (# of related papers)
Majid Ghanavat (1)